UPDATE: Jefferies Raises PT to $8.30 on Boston Scientific Corporation on Favorable 5-Year Outlook

Jefferies maintained Boston Scientific Corporation BSX with a Hold rating and raised the price target from $7.60 to $8.30. Jefferies noted, "Echoing a common refrain in medtech these days, the message from Boston's investor day was that stabilizing core markets and a concerted effort to diversify away from these markets (both products and geographies) will drive better growth. Margins will expand and BSX will slowly return to mid-single-digit sales growth and double-digit earnings. Despite the risks in the outlook it seems already priced into the stock so we stay at Hold." Boston Scientific Corporation closed at $7.59 on Tuesday.